De Morsier Syndrome Associated With Megalocornea: Impact of Hormone Replacement Therapy on the Resolution of Neonatal Cholestasis

De Morsier syndrome, or septo-optic dysplasia (SOD), is a rare congenital malformation characterized by optic nerve hypoplasia, midline brain abnormalities, and pituitary hormone deficiencies. Neonatal presentation can be misleading, particularly when it manifests as cholestatic jaundice. We report the clinical, biochemical, and radiological evaluation of a two-month-old male infant admitted for persistent neonatal cholestatic jaundice, progressive weight faltering, and recurrent hypoglycemia. Slit-lamp examination, comprehensive endocrine workup, and brain magnetic resonance imaging (MRI) were performed to establish the diagnosis. Written informed consent was obtained from the patient's parents (or legal guardians) for publication of this case report and any accompanying images. Physical examination revealed horizontal nystagmus and bilateral megalocornea (diameter > 13 mm). Laboratory investigations showed cholestasis with normal gamma-glutamyl transferase (GGT) levels and recurrent hypoglycemia, which led to the diagnosis of combined anterior pituitary hormone deficiency (growth hormone, thyroid-stimulating hormone, and adrenocorticotropic hormone). Brain MRI confirmed the diagnosis by showing agenesis of the septum pellucidum, bilateral optic nerve hypoplasia, and an ectopic posterior pituitary gland. Targeted hormone replacement therapy with L-thyroxine (10 μg/kg/day) and hydrocortisone (5 mg/kg/day) led to a complete resolution of the cholestasis within three weeks, alongside blood glucose stabilization and weight gain. Neonatal cholestasis is a classic early manifestation of SOD due to impaired bile acid transporter maturation caused by endocrine deficits. Its association with megalocornea highlights the variability of embryonic anterior segment anomalies. Early diagnosis is vital to initiate prompt hormone therapy, ensure hepatic recovery, and optimize neurodevelopmental outcomes.

Authors

Publication Details

Journal
Cureus
Published
2026-08-18
DOI
https://doi.org/10.7759/cureus.114713
Primary Topic
Growth Hormone and Insulin-like Growth Factors
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

De Morsier Syndrome Associated With Megalocornea: Impact of Hormone Replacement Therapy on the Resolution of Neonatal Cholestasis

Meriem Atrassi, Dalal Bensabbahia, Mbaihorem Nicolas, Khellouk Houda
Cureus
Growth Hormone and Insulin-like Growth Factors
article

De Morsier Syndrome Associated With Megalocornea: Impact of Hormone Replacement Therapy on the Resolution of Neonatal Cholestasis

Meriem Atrassi, Dalal Bensabbahia, Mbaihorem Nicolas, Khellouk Houda
article en

Abstract

De Morsier syndrome, or septo-optic dysplasia (SOD), is a rare congenital malformation characterized by optic nerve hypoplasia, midline brain abnormalities, and pituitary hormone deficiencies. Neonatal presentation can be misleading, particularly when it manifests as cholestatic jaundice. We report the clinical, biochemical, and radiological evaluation of a two-month-old male infant admitted for persistent neonatal cholestatic jaundice, progressive weight faltering, and recurrent hypoglycemia. Slit-lamp examination, comprehensive endocrine workup, and brain magnetic resonance imaging (MRI) were performed to establish the diagnosis. Written informed consent was obtained from the patient's parents (or legal guardians) for publication of this case report and any accompanying images. Physical examination revealed horizontal nystagmus and bilateral megalocornea (diameter > 13 mm). Laboratory investigations showed cholestasis with normal gamma-glutamyl transferase (GGT) levels and recurrent hypoglycemia, which led to the diagnosis of combined anterior pituitary hormone deficiency (growth hormone, thyroid-stimulating hormone, and adrenocorticotropic hormone). Brain MRI confirmed the diagnosis by showing agenesis of the septum pellucidum, bilateral optic nerve hypoplasia, and an ectopic posterior pituitary gland. Targeted hormone replacement therapy with L-thyroxine (10 μg/kg/day) and hydrocortisone (5 mg/kg/day) led to a complete resolution of the cholestasis within three weeks, alongside blood glucose stabilization and weight gain. Neonatal cholestasis is a classic early manifestation of SOD due to impaired bile acid transporter maturation caused by endocrine deficits. Its association with megalocornea highlights the variability of embryonic anterior segment anomalies. Early diagnosis is vital to initiate prompt hormone therapy, ensure hepatic recovery, and optimize neurodevelopmental outcomes.

Cureus
Good health and well-being
Openalex Percentile: Top 10%
Growth Hormone and Insulin-like Growth Factors
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

De Morsier Syndrome Associated With Megalocornea: Impact of Hormone Replacement Therapy on the Resolution of Neonatal Cholestasis — Meriem Atrassi, Dalal Bensabbahia, et al. · Cureus (2026) | TGRS Research Map | TGRS